Skip to content
Screener

CorMedix CRMD Q4 2025 Annual earnings

Reported March 5, 2026 · Before market open

Revenue$128.6MBeat by $1.6M
EPS$0.61Miss by $0.25
Revenue estimate$127.0M
EPS estimate$0.86

Next report

Nov 11, 2026 (in 2 months)
Revenue estimate$53.3M
EPS estimate-$0.10

Financials

Q4 2025

Income statement

See full
Revenue$128.6M+312%
Gross profit$117.4M+290%
Operating income$59.1M—
Net income$56.4M—
EPS (diluted)$0.07—

Balance sheet

See full
Cash & equivalents$145.8M+258%
Total debt$4.3M+729%
Total equity$405.3M+379%
Total assets$826.1M+595%

Cash flow

See full
Operating cash flow$94.5M+1,782%
CapEx$1.7M+16,865%
Free cash flow$92.7M+1,749%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$916.32M+86.4%
Enterprise value$774.78M+71.7%
P/E6.1×—
P/S2.9×-8.4×

Profitability

See full
Gross margin92.9%0.0pp
Operating margin48.2%—
Net margin48%—
FCF margin55.4%+33.0pp

Returns & leverage

See full
Return on equity61%—
Debt / equity0×0.0×
Current ratio2.1×-1.3×

Segments

By product

See full
Contract revenue$4.6M—

FAQ

When did CorMedix report Q4 2025 earnings?
CorMedix (CRMD) reported Q4 2025 earnings on March 5, 2026 before market open.
What were CorMedix's Q4 2025 revenue and EPS?
CorMedix reported revenue of $128.6M and eps of $0.61 for Q4 2025.
Did CorMedix beat estimates in Q4 2025?
Revenue beat the consensus estimate of $127.0M by $1.6M. EPS missed the consensus estimate of $0.86 by $0.25.
How did CorMedix's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 312.1% from $31.2M a year earlier and eps grew 177.3% from $0.22.
Where can I find CorMedix's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001213900-26-023881) and the 10-K periodic report (0001213900-26-023889) directly on SEC EDGAR. The filing index links above go to sec.gov.